Trial · NCT01156792
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 58
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period | FP + Placebo | 2.36 | Standard Error 0.03 | Liters (L) | |
| Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period | FP + GSK2190915 100 mg | 2.39 | Standard Error 0.03 | Liters (L) | |
| Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period | FP + GSK2190915 300 mg | 2.40 | Standard Error 0.03 | Liters (L) | |
| Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period | FP + Montelukast | 2.42 | Standard Error 0.03 | Liters (L) | |
| Trough (AM Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) at the End of the 6-week Treatment Period | FP / Salmeterol | 2.43 | Standard Error 0.03 | Liters (L) | |
| Daily Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP + Placebo | 349.19 | Standard Error 4.08 | Liters/minute (L/min) | |
| Daily Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP + GSK2190915 100 mg | 350.14 | Standard Error 4.06 | Liters/minute (L/min) | |
| Daily Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP + GSK2190915 300 mg | 354.96 | Standard Error 4.07 | Liters/minute (L/min) | |
| Daily Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP + Montelukast | 354.17 | Standard Error 4.05 | Liters/minute (L/min) | |
| Daily Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP / Salmeterol | 361.33 | Standard Error 4.05 | Liters/minute (L/min) | |
| Daily Evening PEF Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP + Placebo | 354.06 | Standard Error 4.03 | L/min | |
| Daily Evening PEF Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP + GSK2190915 100 mg | 355.71 | Standard Error 4.02 | L/min | |
| Daily Evening PEF Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP + GSK2190915 300 mg | 359.16 | Standard Error 4.03 | L/min | |
| Daily Evening PEF Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP + Montelukast | 358.88 | Standard Error 4.01 | L/min | |
| Daily Evening PEF Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP / Salmeterol | 364.35 | Standard Error 4.00 | L/min | |
| Daily (Average of Morning and Evening) PEF Averaged Over the Last 3 Weeks of the 6 -Week Treatment Period Between GSK2190915 and Montelukast Groups | FP + GSK2190915 100 mg | 352.37 | Standard Error 3.90 | L/min | |
| Daily (Average of Morning and Evening) PEF Averaged Over the Last 3 Weeks of the 6 -Week Treatment Period Between GSK2190915 and Montelukast Groups | FP + GSK2190915 300 mg | 356.16 | Standard Error 3.91 | L/min | |
| Daily (Average of Morning and Evening) PEF Averaged Over the Last 3 Weeks of the 6 -Week Treatment Period Between GSK2190915 and Montelukast Groups | FP + Montelukast | 356.52 | Standard Error 3.90 | L/min | |
| Daily Asthma Symptom Score Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP + Placebo | 2.26 | Standard Error 0.12 | Score on a scale | |
| Daily Asthma Symptom Score Averaged Over the Last 3 Weeks of the 6-week Treatment Period | FP + GSK2190915 100 mg | 2.26 | Standard Error 0.12 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01156792/results